Genomic Assay Predicts Probability of Heart Transplant Rejection
|
By LabMedica International staff writers Posted on 05 Mar 2014 |
Results obtained over time by a gene expression assay used to monitor heart transplant patients for signs of rejection may be able to predict the likelihood of rejection in the future.
The AlloMap Molecular Expression Test, which is manufactured and performed by the biomedical company XDx (Brisbane, CA, USA), is an in vitro diagnostic multivariate index assay (IVDMIA) testing service. The assay, which is performed in a single laboratory, assesses the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing may be used to evaluate transplant patients aged 15 years or older from at least two months after the transplant. It is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.
AlloMap, which measures the expression levels of 11 rejection-related genes from a patient's blood sample, received clearance from the [US] Food and Drug Administration (FDA) in 2008 and it is now routinely used by a majority of American heart transplant centers to monitor low-risk patients during follow-up care, resulting in a substantial reduction in the number of heart-muscle biopsies.
Investigators at the University of California, Los Angeles (USA) recently evaluated data obtained by a study of 600 heart transplant recipients who had been monitored by routine biopsy or with the AlloMap test. They found that the variability of a heart recipient's gene expression profiling test scores over time could provide prognostic utility. This information was independent of the probability of acute cellular rejection at the time of testing.
"The AlloMap was the first FDA-cleared test allowing transplant centers to rule out rejection at the time of the visit," said first author Dr. Mario Deng, professor of medicine at the University of California, Los Angeles. "But until now, it has never been used to predict future events. For the first time, we can use genomic testing over multiple patient visits to go beyond intuition to understand not just how patients are doing now but how they are likely to be a few months from now. It is another step toward personalized medicine."
The study was published in the January 31, 2014, online edition of the journal Transplantation.
Related Links:
XDx
University of California, Los Angeles
The AlloMap Molecular Expression Test, which is manufactured and performed by the biomedical company XDx (Brisbane, CA, USA), is an in vitro diagnostic multivariate index assay (IVDMIA) testing service. The assay, which is performed in a single laboratory, assesses the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing may be used to evaluate transplant patients aged 15 years or older from at least two months after the transplant. It is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.
AlloMap, which measures the expression levels of 11 rejection-related genes from a patient's blood sample, received clearance from the [US] Food and Drug Administration (FDA) in 2008 and it is now routinely used by a majority of American heart transplant centers to monitor low-risk patients during follow-up care, resulting in a substantial reduction in the number of heart-muscle biopsies.
Investigators at the University of California, Los Angeles (USA) recently evaluated data obtained by a study of 600 heart transplant recipients who had been monitored by routine biopsy or with the AlloMap test. They found that the variability of a heart recipient's gene expression profiling test scores over time could provide prognostic utility. This information was independent of the probability of acute cellular rejection at the time of testing.
"The AlloMap was the first FDA-cleared test allowing transplant centers to rule out rejection at the time of the visit," said first author Dr. Mario Deng, professor of medicine at the University of California, Los Angeles. "But until now, it has never been used to predict future events. For the first time, we can use genomic testing over multiple patient visits to go beyond intuition to understand not just how patients are doing now but how they are likely to be a few months from now. It is another step toward personalized medicine."
The study was published in the January 31, 2014, online edition of the journal Transplantation.
Related Links:
XDx
University of California, Los Angeles
Latest Molecular Diagnostics News
- Genome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
- Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening
- Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
- Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
- FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs
- Whole Transcriptome Analysis Expands Understanding of Cancer Gene Fusions
- Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
- AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
- Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
- Genetic Test Improves Risk Prediction for Open-Angle Glaucoma
- Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
- Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
- Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
- Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations
Channels
Clinical Chemistry
view channel
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more
Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







